Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“New Study Alert
Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma cell disorder that can progress to multiple myeloma (MM).
Emerging evidence suggests that GLP-1 receptor agonists (GLP-1 RAs)—commonly used for diabetes and obesity—may also have anti-neoplastic effects.
Using the TriNetX global network, this retrospective cohort study of 30,034 matched patients with MGUS and metabolic comorbidities found that GLP-1 RA therapy was associated with:
- Improved progression-free survival (HR 0.63)
- Improved overall survival (HR 0.61)
- Reduced risk of progression to MM (HR 0.82)
Although GLP-1 RA users showed fewer cardiovascular events (MI, stroke, HF), these were not statistically significant over time.
Takeaway: GLP-1 RAs may confer both metabolic and survival benefits in MGUS—highlighting a potential role beyond glycemic control.”
Title: GLP-1 receptor agonists in patients with MGUS: A real-world propensity-matched study
Authors: Anastasios Tentolouris, Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Evangelos Terpos, Efstathios Kastritis, Ernesto Ruiz Duque, Meletios-Athanasios Dimopoulos, Maria Gavriatopoulou, Alexandros Briasoulis
Read the full article on European Journal of Clinical Investigation
More posts featuring Yan Leyfman on OncoDaily.